Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT01225003
First received: October 19, 2010
Last updated: September 28, 2011
Last verified: October 2010
  Purpose

In this study, we evaluate the role of diffusion kurtosis imaging (DKI) and MR spectroscopy (MRS), two advanced imaging techniques in magnetic resonance (MR) in grading and detection of microscopic infiltrating tumour in gliomas. These parameters are of utmost importance in optimal choice and planning of treatment.

Patients treated with gliomatous brain tumours are included voluntarily. They undergo one imaging session on a 3T MR scanner prior to treatment.

DKI data are quantitively analyzed in order to estimate specific parameters in normal appearing white matter, grey matter, tumor and peritumoral edema. MRS data are analyzed quantitatively and qualitatively with peak integration, ratio calculation and classification algorithms. Histological confirmation is obtained at subsequent surgery.

Information from this study can be of significant importance in avoiding brain biopsies. Furthermore, information on microscopic tumour spread can be used during neurosurgery or in radiotherapy planning. An important advantage of these advanced MR techniques is the non-invasivity and the lack of ionizing radiation, two important issues in this relatively young patient population.


Condition
Gliomas

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Diffusion Kurtosis Imaging en MR Spectroscopy in Grading and the Characterization of Tumour Infiltration in Gliomas

Resource links provided by NLM:


Further study details as provided by Universitaire Ziekenhuizen Leuven:

Biospecimen Retention:   Samples Without DNA

standard neurosurgical procedure to obtain specimens; standard histopathological examination


Estimated Enrollment: 30
Study Start Date: July 2010
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

patients diagnosed with a gliomatuous brain tumor, prior to treatment

Criteria

Inclusion Criteria:

  • diagnosis of gliomatous brain tumour

Exclusion Criteria:

  • younger than 18 years of age
  • prior treatment
  • history of neurological or neurosurgical treatment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01225003

Locations
Belgium
University Hospitals of Leuven
Leuven, Vlaams-Brabant, Belgium, 3001
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Investigators
Principal Investigator: Stefan Sunaert, MD, PhD University Hospitals Leuven
Principal Investigator: Uwe Himmelreich, PhD Catholic University Leuven
  More Information

No publications provided

Responsible Party: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT01225003     History of Changes
Other Study ID Numbers: S52302
Study First Received: October 19, 2010
Last Updated: September 28, 2011
Health Authority: Belgium: Institutional Review Board

Keywords provided by Universitaire Ziekenhuizen Leuven:
gliomas
magnetic resonance
diffusion kurtosis imaging
MR spectroscopy
grading

Additional relevant MeSH terms:
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on April 20, 2014